Row PG, et al. Membranous nephropathy. Long-term follow-up and association with neoplasia. Q J Med 1975; 44:207–239. https://doi.org/10.1093/oxfordjournals.qjmed.a067422
Cahen R, et al. Aetiology of membranous glomerulonephritis: A prospective study of 82 adult patients. Nephrol Dial Transplant 1989; 4:172–180. doi: 10.1093/oxfordjournals.ndt.a091852
Thet Z, et al. Critical evaluation of cancer risks in glomerular disease. Transl Oncol [published online ahead of print February 24, 2022]. doi: 10.1016/j.tranon.2022.101376; https://www.sciencedirect.com/science/article/pii/S1936523322000389?via%3Dihub
Leeaphorn N, et al. Prevalence of cancer in membranous nephropathy: A systematic review and meta-analysis of observational studies. Am J Nephrol 2014; 40:29–35. doi: 10.1159/000364782
Bjørneklett R, et al. Long-term risk of cancer in membranous nephropathy patients. Am J Kidney Dis 2007; 50:396–403. doi: 10.1053/j.ajkd.2007.06.003
Zhang D, et al. Clinicopathological features in membranous nephropathy with cancer: A retrospective single-center study and literature review. Int J Biol Markers 2019; 34:406–413. doi: 10.1177/1724600819882698
Qu Z, et al. Absence of glomerular IgG4 deposition in patients with membranous nephropathy may indicate malignancy. Nephrol Dial Transplant 2012; 27:1931–1937. doi: 10.1093/ndt/gfr534
Heaf JG, et al. Quantification of cancer risk in glomerulonephritis. BMC Nephrol 2018; 19:27. doi: 10.1186/s12882-018-0828-2
Pani A, et al. Glomerular diseases and cancer: Evaluation of underlying malignancy. J Nephrol 2016; 29:143–152. doi: 10.1007/s40620-015-0234-9
Nissan E, et al. The usefulness of [18F]FDG-PET/CT in detecting and managing cancers with unknown primary site depends on histological subtype. Sci Rep 2021; 11:17732. doi: 10.1038/s41598-021-96451-z
Caza TN, et al. NELL1 is a target antigen in malignancy-associated membranous nephropathy. Kidney Int 2021; 99:967–976. doi: 10.1016/j.kint.2020.07.039
Khan MB, et al. Complete resolution of paraneoplastic membranous nephropathy following curative therapy of triple-negative breast cancer. Cureus 2021; 13:e18125. doi: 10.7759/cureus.18125
Adlington D, et al. Remission of membranous nephropathy after treatment of localised prostate cancer. Case Rep Nephrol Dial 2019; 9:79–84. doi: 10.1159/000500948; https://core.ac.uk/download/pdf/237441013.pdf